# Josh Lehrer

> Josh Lehrer is a physician-scientist and biotech executive serving as CEO of Marea Therapeutics, a clinical-stage company harnessing human genetics to develop first-in-class medicines for cardiometabolic diseases. A cardiologist by training with degrees from Harvard, Cambridge, and UCSF, Lehrer brings over two decades of drug development experience spanning Genentech, Global Blood Therapeutics (where he oversaw the FDA approval of Oxbryta for sickle cell disease), and Graphite Bio. At Marea, he has led the company from a Third Rock Ventures incubation to a $190 million-funded enterprise with two clinical-stage programs showing strong early efficacy data, including a 53% reduction in remnant cholesterol with MAR001 published in The Lancet.

- **Role:** Chief Executive Officer at Marea Therapeutics
- **Organizations:** Marea Therapeutics, Fulcrum Therapeutics (Board of Directors), Stanford School of Medicine (Adjunct Faculty)
- **Nationality:** American
- **Education:** A.B. in Biochemical Sciences, Harvard University, M.Phil. in Biological Sciences, University of Cambridge, M.D. (Doctor of Medicine), UCSF School of Medicine, Internal Medicine Residency, UCSF, Cardiology Fellowship, Stanford School of Medicine
- **Known for:** Oversaw development and FDA approval of Oxbryta (voxelotor), the first drug approved for sickle cell disease in decades, at Global Blood Therapeutics, Led Marea Therapeutics to secure $190 million in combined Series A and Series B funding, Led MAR001 to positive Phase 2a results with 53% reduction in remnant cholesterol, published in The Lancet (2025)

## Career timeline

- **2009** — Joined Genentech, leading clinical development programs through proof of concept in multiple indications; also involved in business development and cardiovascular safety oversight
- **2013** — Left Genentech after leading multiple clinical programs through proof of concept
- **2013-2020** — Joined Global Blood Therapeutics as Vice President of Clinical Development, rising to Chief Medical Officer; oversaw development and FDA approval of Oxbryta (voxelotor) for sickle cell disease
- **2020** — Appointed President and Chief Executive Officer of Graphite Bio, a gene-editing biotechnology company
- **2023** — Joined Marea Therapeutics as Chief Executive Officer (October 2023), company incubated by Third Rock Ventures
- **2024** — Led Marea Therapeutics' public launch with $190 million in combined Series A and Series B financing (June 2024)
- **2025** — MAR001 Phase 2a results published in The Lancet showing 53% reduction in remnant cholesterol; Phase 2b study (TYDAL-TIMI 78) underway
- **2026** — MAR002 Phase 1 positive topline data unveiled; appointed to Fulcrum Therapeutics Board of Directors (April 2026)

## Achievements

- Oversaw development and FDA approval of Oxbryta (voxelotor), the first drug approved for sickle cell disease in decades, at Global Blood Therapeutics
- Led Marea Therapeutics to secure $190 million in combined Series A and Series B funding
- Led MAR001 to positive Phase 2a results with 53% reduction in remnant cholesterol, published in The Lancet (2025)
- Led MAR002 to positive Phase 1 results showing 52% IGF-1 suppression, with potential best-in-disease profile for acromegaly
- Presented at the 44th Annual J.P. Morgan Healthcare Conference (January 2026)
- Appointed to Fulcrum Therapeutics Board of Directors (April 2026)
- Fellow of the American College of Cardiology (FACC)
- Adjunct Faculty at Stanford School of Medicine Division of Cardiology
- Trained at three of America's elite institutions: Harvard, Cambridge, and UCSF

## Latest updates

- **2026-04** — Appointed to Fulcrum Therapeutics Board of Directors as Class III independent director
- **2026-01** — Presented Marea Therapeutics at the 44th Annual J.P. Morgan Healthcare Conference; MAR002 positive Phase 1 topline data unveiled
- **2025-05** — MAR001 Phase 2a data published in The Lancet, showing 53% reduction in remnant cholesterol and triglycerides
- **2024-06** — Marea Therapeutics publicly launched with $190 million in Series A and Series B financing

## Links

- Website: https://www.mareatx.com/team/josh-lehrer-2/
- LinkedIn: http://www.linkedin.com/in/josh-lehrer-8b33199

---

Profile page: https://yespress.io/josh-lehrer
Published by YesPress — https://yespress.io
Last updated: 2026-05-14